Comparative Pharmacology
Head-to-head clinical analysis: METHYLPREDNISOLONE ACETATE versus SOLU MEDROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METHYLPREDNISOLONE ACETATE versus SOLU MEDROL.
METHYLPREDNISOLONE ACETATE vs SOLU-MEDROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methylprednisolone acetate is a synthetic glucocorticoid that binds to the glucocorticoid receptor, modulating gene expression to suppress inflammation, immune response, and adrenal function. It inhibits phospholipase A2, reduces prostaglandin and leukotriene synthesis, and decreases cytokine production.
Corticosteroid with anti-inflammatory and immunosuppressive properties; suppresses inflammatory cytokines and immune cell activity.
40-80 mg intramuscular (IM) or intra-articular (IA) injection; for IM use, dose may be repeated every 1-4 weeks as needed. Maximum single IM dose: 120 mg.
IV or IM: 10-40 mg methylprednisolone (as sodium succinate) every 4-6 hours; high-dose pulse therapy: 30 mg/kg IV over 30-60 minutes every 4-6 hours for 48-72 hours.
None Documented
None Documented
Terminal half-life: 3-3.5 hours; correlates with duration of anti-inflammatory effect due to receptor-mediated action.
Terminal elimination half-life: 2.5–3.5 hours. In clinical context, the biologic half-life (suppression of HPA axis) is longer (24–36 hours) due to tissue retention of active metabolites.
Renal: <10% unchanged; extensive hepatic metabolism to inactive metabolites primarily excreted renally as glucuronides and sulfates.
Renal: approximately 80% as metabolites (glucuronide and sulfate conjugates) and unchanged drug; biliary/fecal: less than 5%.
Category D/X
Category C
Corticosteroid
Corticosteroid